Kilitch Drugs [KILITCH] vs Gujarat Themis [GUJTHEM] Detailed Stock Comparison

Kilitch Drugs (India) Ltd.

NSE
Loading...

Gujarat Themis Biosyn Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Kilitch Drugs (India) Ltd. wins in 8 metrics, Gujarat Themis Biosyn Ltd. wins in 11 metrics, with 0 ties. Gujarat Themis Biosyn Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Kilitch Drugs (India) Ltd. Gujarat Themis Biosyn Ltd. Better
P/E Ratio (TTM) 20.30 73.73 Kilitch Drugs (India) Ltd.
Price-to-Book Ratio 1.98 13.36 Kilitch Drugs (India) Ltd.
Debt-to-Equity Ratio 31.65 27.04 Gujarat Themis Biosyn Ltd.
PEG Ratio -0.31 -17.55 Kilitch Drugs (India) Ltd.
EV/EBITDA 18.54 52.76 Kilitch Drugs (India) Ltd.
Profit Margin (TTM) 12.76% 29.99% Gujarat Themis Biosyn Ltd.
Operating Margin (TTM) 9.69% 40.16% Gujarat Themis Biosyn Ltd.
EBITDA Margin (TTM) 9.69% 40.16% Gujarat Themis Biosyn Ltd.
Return on Equity 13.32% 19.64% Gujarat Themis Biosyn Ltd.
Return on Assets (TTM) 8.54% 16.19% Gujarat Themis Biosyn Ltd.
Free Cash Flow (TTM) $-293.31M $-251.22M Gujarat Themis Biosyn Ltd.
Dividend Yield N/A 0.17% N/A
1-Year Return -15.49% 31.69% Gujarat Themis Biosyn Ltd.
Price-to-Sales Ratio (TTM) 2.69 22.23 Kilitch Drugs (India) Ltd.
Enterprise Value $5.34B $36.09B Gujarat Themis Biosyn Ltd.
EV/Revenue Ratio 2.58 22.65 Kilitch Drugs (India) Ltd.
Gross Profit Margin (TTM) 42.60% 83.29% Gujarat Themis Biosyn Ltd.
Revenue per Share (TTM) $62 $15 Kilitch Drugs (India) Ltd.
Earnings per Share (Diluted) $7.85 $4.40 Kilitch Drugs (India) Ltd.
Beta (Stock Volatility) 0.03 -0.17 Gujarat Themis Biosyn Ltd.

Kilitch Drugs (India) Ltd. vs Gujarat Themis Biosyn Ltd. Stock Performance Analysis

Loading Price Chart...

KILITCH
GUJTHEM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Kilitch Drugs (India) Ltd.-3.33%-1.11%16.16%12.55%3.84%-0.60%
Gujarat Themis Biosyn Ltd.1.72%7.42%6.10%33.40%-1.19%-10.34%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Kilitch Drugs (India) Ltd.-15.49%72.82%131.81%1,009.43%521.22%188.64%
Gujarat Themis Biosyn Ltd.31.69%84.69%84.69%84.69%84.69%84.69%

Performance & Financial Health Analysis: Kilitch Drugs (India) Ltd. vs Gujarat Themis Biosyn Ltd.

MetricKILITCHGUJTHEM
Market Information
Market Cap i₹5.57B₹35.41B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i113,56179,452
90 Day Avg. Volume i69,256106,446
Last Close₹172.66₹401.80
52 Week Range₹117.25 - ₹250.00₹225.05 - ₹479.00
% from 52W High-30.94%-16.12%
All-Time High₹500.00 (Jul 15, 2025)₹479.00 (Oct 27, 2025)
% from All-Time High-65.47%-16.12%
Growth Metrics
Quarterly Revenue Growth-0.04%0.10%
Quarterly Earnings Growth-0.26%-0.04%
Financial Health
Profit Margin (TTM) i0.13%0.30%
Operating Margin (TTM) i0.10%0.40%
Return on Equity (TTM) i0.13%0.20%
Debt to Equity (MRQ) i31.6527.04
Cash & Liquidity
Book Value per Share (MRQ)₹80.61₹24.29
Cash per Share (MRQ)₹24.88₹0.92
Operating Cash Flow (TTM) i₹8.18M₹970.68M
Levered Free Cash Flow (TTM) i₹267.01M₹487.72M
Dividends
Last 12-Month Dividend Yield iN/A0.17%
Last 12-Month Dividend i₹0.00₹0.67

Valuation & Enterprise Metrics Analysis: Kilitch Drugs (India) Ltd. vs Gujarat Themis Biosyn Ltd.

MetricKILITCH (Apr 24, 2026)GUJTHEM (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i20.3073.73
Forward P/E i10.42N/A
PEG Ratio i-0.31-17.55
Price to Sales (TTM) i2.6922.23
Price to Book (MRQ) i1.9813.36
Market Capitalization
Market Capitalization i₹5.57B₹35.41B
Enterprise Value i₹5.34B₹36.09B
Enterprise Value Metrics
Enterprise to Revenue i2.5822.65
Enterprise to EBITDA i18.5452.76
Risk & Other Metrics
Beta i0.03-0.17
Book Value per Share (MRQ) i₹80.61₹24.29

Financial Statements Comparison: Kilitch Drugs (India) Ltd. vs Gujarat Themis Biosyn Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricKILITCH (2025)GUJTHEM (2025)
Revenue/Sales i1.97B1.51B
Cost of Goods Sold i1.07B318.78M
COGS % of Revenue i54.1%21.1%
Gross Profit i904.87M1.19B
Gross Margin i45.9%78.9%
Research & Development iN/A34.37M
Operating Income (EBIT) i286.34M642.49M
Operating Margin i14.5%42.6%
EBITDA i386.66M713.04M
EBITDA Margin i19.6%47.3%
Pre-Tax Income i344.74M655.38M
Pre-Tax Income % of Revenue i17.5%43.5%
Income Tax i95.34M167.66M
Income Tax % of Revenue i4.8%11.1%
Net Income (Profit) i249.40M487.72M
Profit Margin i12.6%32.3%

Balance Sheet & Liquidity Metrics

MetricKILITCH (2025)GUJTHEM (2025)
Cash & Equivalents i97.49M116.94M
Total Current Assets i1.74B519.73M
Total Current Assets % of Revenue i88.2%34.5%
Total Current Liabilities i843.10M205.60M
Total Current Liabilities % of Revenue i42.7%13.6%
Long-Term Debt i277.70M296.36M
Long-Term Debt % of Revenue i14.1%19.7%
Total Shareholders Equity i2.00B2.48B
Retained Earnings i1.11B2.37B
Retained Earnings % of Revenue i56.2%157.4%
Property, Plant & Equipment i41.13M411.30M

Cash Flow Statement Comparison

MetricKILITCH (2025)GUJTHEM (2025)
Operating Cash Flow i8.18M970.68M
Operating Cash Flow % of Revenue i0.4%64.4%
Capital Expenditures iN/A-1.16B
Free Cash Flow i-293.31M-251.22M
FCF Margin i-14.9%-16.7%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricKILITCHGUJTHEM
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i34.96M108.97M
Float Shares i9.61M29.52M
% Held by Insiders i72.22%71.98%
% Held by Institutions i0.00%1.18%
% Held by Public i27.78%26.84%

Dividend Analysis & Yield Comparison: Kilitch Drugs (India) Ltd. vs Gujarat Themis Biosyn Ltd.

MetricKILITCHGUJTHEM
Last 12-Month Dividend i₹0.00₹0.67
Last 12-Month Dividend Yield iN/A0.17%
3-Year Avg Annual Dividend i₹0.00₹0.22
3-Year Avg Dividend Yield iN/A0.17%
3-Year Total Dividends i₹0.00₹0.67
Ex-Dividend DateN/ASep 04, 2025